Dr. Yooni Kim, Vice President of Clinical Services at Novotech, Delivers Keynote Address at Veeva Korea Summit
SEOUL, Korea, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, announced today that Dr. Yooni Kim, Vice President of Clinical Services at Novotech, served as a keynote speaker at the Veeva Korea Summit this week in Seoul, Korea.
Novotech has been utilizing Veeva’s technology for over a decade and was an early adopter of these cutting-edge solutions to enhance drug development programs for its biotech clients.
According to Dr. Kim, “The customized Novotech Veeva Suite Ecosystem offers our biotech clients state-of-the-art streamlined procedures and enhanced data visibility, along with advanced trial planning and predictive capabilities."
During her keynote address, Dr. Kim underscored several key advantages that the Novotech Veeva Platform, including the Vault Suite, is providing to clients. These benefits include:
- Master trial, site, and investigator data shared across systems
- Shared workflow and reporting - multiple on platform workflows, task assignment, PD escalation, document review/authoring
- One application means one login to access reporting across TMF, start-up, CTMS, feasibility
- Auto-filing of study start-up documents and monitoring content into TMF, on platform TMF review and document QC
- Reuse documents across countries, trials
- Regulatory and IRB/IEC submission milestone tracking/ package review on platform
- Site Greenlight
- Automated visit tracking
- Payments tracking
Dr. Kim further elaborated, noting that the Vault Clinical Suite facilitates faster trial execution and provides up-to-the-minute insights.
She added, "The platform enhances efficiency and ensures high quality by promoting shared data and content, resulting in improved accuracy in trial planning and reporting." Among the other advantages, she pointed out were:
- Scalability to support support harmonized clinical trial delivery across Novotech.
- Improved project delivery for our clients including expediting start up timelines.
- Reporting - empower real time, end user driven and on-platform reporting capabilities providing robust data to both Novotech and our clients, to enable active management of our trials and maintain effective trial and portfolio oversight.
- Have one single-source to manage feasibility information and process including on-platform survey creation and dynamic reporting capabilities.
- Simplified, cost effective future integrations.
- Enable Clinical Systems support services under one platform, provide rapid study set-up, and one set of accounts and contacts.
Novotech has more than 3,000 employees operating across 25 geographies with 34 office locations, including the US, Greater China, South Korea, Australia, New Zealand, and Europe.
The global CRO offers biotechs a unique and unparalleled suite of early to late-phase services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023 and the Best Cell & Gene Therapy CRO 2022 and 2023 awards. Additionally, the company was honored with the Asia-Pacific Contract Research Organization Company of the Year Award in 2022 and 2023. Its commitment to collaboration is evident in the 50 Leading Site Partnership agreements it has signed over the past three years.
Founded in 1997, Novotech is internationally recognized as the leading Asia Pacific centred Contract Research Organization (CRO) with global execution capabilities. The Company has established itself as a clinical CRO with labs, phase I facilities, drug development consulting services and regulatory expertise. It has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech employs over 3,000 staff globally across 34 office locations. Novotech is positioned to serve as a partner and ally to small and medium-sized biotech, biopharma and pharma sponsors seeking to conduct clinical trials in Asia Pacific, the US and Europe.
For more information visit Novotech CROTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Bahrain unveils its National Energy Strategy and steps up commitment to achieve net zero emissions by 206030.11.2023 15:53:48 CET | Press release
MANAMA, Bahrain, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bahrain today unveiled its National Energy Strategy: a clear, credible, and responsible pathway to reaching the climate targets the Kingdom pledged to achieve at COP26, namely a 30 percent reduction in emissions by 2035 on the road to net-zero emissions by 2060. The Strategy is rooted in the twin objectives of decarbonizing Bahrain’s economy while ensuring reliable and affordable access to the energy the Kingdom needs to sustain and, indeed, accelerate its growth. It is one of 6 priority sector strategies that stem from the Kingdom’s forward-looking Economic Recovery Plan. Recognizing that there are many ways to approach decarbonization, with some countries focusing on a regulatory approach and others focusing on industry-led initiatives, the Kingdom leveraged its small country advantage to opt for a partnership model. The Strategy is the product of genuine collaboration between government and industry. It did this in an effort to harn
VALOE EXTENDS THE SUBSCRIPTION PERIOD OF THE CONVERTIBLE BOND 1/202330.11.2023 15:15:00 CET | Press release
Valoe Corporation Stock Exchange Release 30 November 2023 at 16.15 (Finnish time) The Board of Directors of Valoe Corporation has resolved to extend the subscription period of the Convertible Bond 1/2023 disclosed on 14 July 2023 until 29 December 2023 at 6.00 pm. In Mikkeli on 30 November 2023 Valoe Corporation BOARD OF DIRECTORS For more information: CEO Iikka Savisalo, Valoe Corporation tel. +358 40 521 6082 email: firstname.lastname@example.org Distribution: Nasdaq Helsinki Oy Main media www.valoe.com Valoe Corporation specializes in the clean energy, especially in photovoltaic solutions. Valoe provides PV technology based on its own back contact technology and related projects, project design and technology consulting. Valoe also provides manufacturing technology for PV modules, module manufacturing lines, modules and key components for modules, as well as IBC solar cells manufactured at the Company’s factory in Lithuania. Valoe is headquartered in Mikkeli, Finland, with production faci
Scatec awarded battery storage project for 103 MW in government tender in South Africa30.11.2023 14:53:04 CET | Press release
Oslo, 30 November 2023: Scatec ASA has been awarded preferred bidder status for the Mogobe (Ferrum) battery energy storage project totalling 103 MW/ 412 MWh under the first bid window of the Battery Energy Storage Independent Power Producer Procurement Programme (BESIPPPP) in South Africa, by the Department of Mineral Resources and Energy. Scatec will dispatch power under a 15-year power purchase agreement (PPA). “This marks another significant achievement for Scatec in South Africa and for the renewable energy transition in the country. Today’s award reaffirms our standing as a leading renewable energy player in South Africa. We applaud the South African government’s commitment and dedication to the battery storage procurement programme,” says Scatec CEO Terje Pilskog. Building on the experience garnered from our hybrid solar and battery storage projects at Kenhardt, we have established ourselves as a frontrunner in the dispatchable renewable energy landscape of South Africa and the A
Correction: New terms for DK0009414252 only english version30.11.2023 14:47:05 CET | Press release
To Nasdaq Copenhagen A/S 30th November 2023 Announcement no. 111/2023 Final terms for bonds to be listed 5thDecember 2023 On 5th December 2023, Jyske Realkredit A/S will be listing new Covered Bonds (SDO). Final terms for the bonds are attached to this announcement. The full prospectus for the Bond consist of the attached final terms and the previously disclosed ”Base Prospectus for the issue of Covered Bonds (SDO), Mortgage bonds (“RO”) and Mortgage Bonds (RO) and bonds issued pursuant to Section 15 of the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act (Section 15 Bonds).”, dated June 29th, 2023. Jyske Realkredit’s base prospectus is available on Jyske Realkredit’s home page jyskerealkredit.com Yours sincerely, Jyske Realkredit A/S www.jyskerealkredit.com Please observe that the Danish version of this announcement prevails. Attachments DK0009414096 - Final terms series 1 321.E.ok.25 IT1DK0009414179 - Final terms series 1 321.E.26 IT1DK0009414252 - Final terms series 1
Correction: Kun korrektion i den engelske version30.11.2023 14:47:05 CET | pressemeddelelse
, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Til Nasdaq Copenhagen A/S 30. november 2023 Meddelelse nr. 111/2023 Endelige vilkår for nye obligationer der noteres den 5. december 2023 Jyske Realkredit noterer den 5. december 2023 nye Særligt Dækkede Obligationer (SDO). Med denne meddelelse følger de endelige vilkår for obligationerne. Det samlede prospekt for obligationerne består af vedlagte endelige vilkår og det tidligere offentliggjorte ”Basisprospekt for udstedelse af Særligt Dækkede Obligationer (SDO), Realkreditobligationer (RO) og obligationer i medfør af § 15 i lov om realkreditlån og realkreditobligationer m.v. (§ 15 Obligationer)”, dateret 29. juni 2023. Jyske Realkredits basisprospekt er tilgængeligt på Jyske Realkredits hjemmeside jyskerealkredit.dk. Venlig hilsen Jyske Realkredit www.jyskerealkredit.dk Vedhæftede filer DK0009414252 - Endelige vilkår serie 1 321.E.EUR.26 IT1DK0009414096 - Endelige vilkår serie 1 321.E.ok.25 IT1DK0009414179 - Endelige vilkår serie 1 321.E.26 IT1